Morphological changes in HIV-1 infected patients on antiretroviral therapy without protease inhibitors in Cameroon: A prospective cohort study

Journal of Medical Sciences (Faisalabad)

Volumn 12, Issue 5, 2012, Pages 131-140

  Nguemaim N F ^b   Mbuagbaw, J ^a,c   Teto G ^a   Nkoa, T ^a,d   Same Ekobo A ^a,e   Asonganyi, T ^a  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b UNIVERSITY OF BAMENDA   (Cameroon)

^c UNIVERSITY OF BUEA   (Cameroon)

^d Yaounde Gyneco Obstetrics and Paediatrics Hospital   (Cameroon)

^e University Teaching Hospital Yaounde   (Cameroon)

Author keywords

Antiretroviral drugs; HIV; HIV negative persons; Lipids; Pathologies

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BUFFALO HUMP; CAMEROON; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HIP CIRCUMFERENCE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID METABOLISM; LIPOATROPHY; LIPOHYPERTROPHY; LIPOMA; MAJOR CLINICAL STUDY; MALE; PATHOLOGICAL ANATOMY; PATIENT CARE; PREVALENCE; PROSPECTIVE STUDY; VIRUS LOAD; WAIST CIRCUMFERENCE; XANTHELASMA;

EID: 84872132816     PISSN: 16824474     EISSN: 18125727     Source Type: Journal    
DOI: 10.3923/jms.2012.131.140     Document Type: Article

References (38)

1. Baril, J.G., P. Junod, R. LeBlanc, H. Dion and R. Therrien et al., 2005. HIV-associated lipodystrophy syndrome: A review of clinical aspects. C. J. Infec. Dis. Med. Microbiol., 16: 233-243.
2. Bogner, J.R., V. Vielhauer, R.A. Beckmann, G. Michl, L. Wille, B. Salzberger and F.D. Goebel, 2001. Stavudine versus zidovudine and the development of lipodystrophy. J. Acquir. Immune. Defic. Syndr., 27: 237-244.
3. Brinkman, K., J.A. Smeitink J.A. Romijn and P. Reiss, 1999. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet, 354: 1112-1115.
4. Caron, M., M. Auclair, H. Sterlingot, M. Kornprobst and J. Capeau, 2003. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS., 17: 2437-2444.
5. Carr, A. and D.A. Cooper, 2000. Adverse effects of antiretroviral therapy. Lancet, 356: 1423-1430.
6. Carr, A., K. Samaras, D.J. Chisholm and D.A. Cooper, 1998. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet, 351: 1881-1883.
7. Chen, C.H., M. Vazquez-Padua and Y.C. Cheng, 1991. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol., 39: 625-628.
8. Chene, G., E. Angelini, L. Cotte, J.M. Lang and P. Morlat et al., 2002. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin. Infect. Dis., 34: 649-657.
9. Chuapai, Y., S. Kiertiburanakul, K. Malathum and S. Sungkanuparph, 2007. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected thai patients receiving antiretroviral therapy. J. Med. Assoc. Thai., 90: 452-458.
10. Cossarizza, A., C. Mussini and A. Vigano, 2001. Mitochondria in the pathogenesis of lipodystrophy induced by anti-HIV antiretroviral drugs: Actors or bystanders? Bioessays, 23: 1070-1080.
11. Dezii, C.M., K.A. Lichtenstein, J.F. Maa and S.L. Hodder, 2003. Significant correlation between low nadir CD4 and the incidence of fat wasting but not lipodystrophy without fat wasting. Proceedings of the 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, July 8-11, 2003, Paris-.
12. Domingo, P., A. Perez, O.H. Torres, J.A. Montiel and G. Vazquez, 1999. Lipodystrophy in HIV-1-infected patients. Lancet, 354: 868-868.
13. Domingo, P., M.A. Sambeat, A. Perez, J. Ordonez, J. Rodriguez and G. Vazquez, 2003. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: Role of physical activity as a protective factor. Antivir. Ther., 8: 223-231.
14. Galli, M., C. Gervasoni, A.L. Ridolfo, D. Trabattoni and S. Santambrogio et al., 2003. Cytokine production in women with antiretroviral treatment-associated breast fat accumulation and limb wasting. J. Acquir. Immune Defic. Syndr., 17: S155-S161.
15. Grundfeld, C., M. Pang, W. Doerrler, J.K. Shigenaga, P. Jensen and K.R. Feingold, 1992. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endecrinol. Metab., 74: 1045-1052.
16. Hotamisligil, G.S., P. Arner, J.F. Caro, R.L. Atkinson and B.M. Spiegelman, 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest., 95: 2409-2415.
17. Hruz, P.W., H. Murata and M. Mueckler, 2001. Adverse metabolic consequences of HIV protease inhibitor therapy: The search for a central mechanism. Am. J. Physiol. Endocrinol. Metab., 280: E549-E553.
18. Jani, L.V., G. Janossy, A. Iqbal, F.S. Mhalu and E.F. Lyamuya et al., 2001. Affordable CD4+ T cell counts by flow cytometry. II. The use of fixed whole blood in resource-poor settings. J. Immunol. Methods., 257: 145-154.
19. Joly, V., P. Flandre, V. Meiffredy, N. Leturque, M. Harel, J.P. Aboulker and P. Yeni, 2002. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. J. Acquir. Immune Defic. Syndr., 16: 2447-2454.
20. Kakuda, T.N., 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther., 22: 685-708.
21. Kim, M.J., P. Leclercq, E. Lanoy, P. Cervera and B. Antuna-Puente et al., 2007. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: The ANRS EP29 Lipostop study. Antiviral Therapy, 12: 1273-1283.
22. Kudlow, B.A., S.A. Jameson and B.K. Kennedy, 2005. HIV protease inhibitors block adipocyte differentiation independently of lamin A/C. Acquir. Immune Defic. Syndr., 19: 1565-1573.
23. Lagathu, C., B. Eustace, M. Prot, D. Frantz and Y. Gu et al., 2007. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antiviral Therapy, 12: 489-500.
24. Ledru, E., N. Chriteff, O. Patey, P. de Truchis, J.C. Melchior and M.L. Gougeon, 2000. Alteration of tumor necrosis factor-α T-cell homeostasis following potent antiretroviral therapy: Contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood, 95: 3191-3198.
25. Lewis, W., 2003. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: Experimental clarifications and persistent clinical questions. Antiviral Res., 58: 189-197.
26. Longley, M.J., P.A. Ropp, S.E. Lim and W.C. Copeland, 1998. Characterization of the native and recombinant catalytic subunit of human DNA polymerase γ: Identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry, 37: 10529-10539.
27. Mallal, S.A., M. John, C.B. Moore, I.R. James and E.J. McKinnon, 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS, 14: 1309-1316.
28. Manuthu, E.M., M.D. Joshi, G.N. Lule and E. Karari, 2008. Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. East Afr. Med. J., 85: 10-17.
29. McComsey, G. and J.E. Maa, 2003. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. Acquir. Immune Defic. Syndr., 13: 539-559.
30. Miller, S.L., K.D. Tipton, D.L. Chinkes, S.E. Wolf and R.R. Wolfe, 2003. Independent and combined effects of amino acids and glucose after resistance exercise. Med. Sci. Sports Exercise, 35: 449-455.
31. Nolan, D., E. Hammond, I. James, E. Mckinnon and S. Mallal, 2003. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir. Ther., 8: 617-626.
32. Rakotoambinina, B., J. Medioni, C. Rabian, V. Jubault, J.P. Jais and J.P. Viard, 2001. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J. Acquir. Immune Defic. Syndr., 27: 443-449.
33. Saves, M., P. Mercie and G. Chene, 2001. Syndrome lipodystrophique et traitements antiretroviraux chez les patients infectes par le VIH-1 [Lipodystrophy and antiretroviral therapy in patients infected with HIV-1]. Med. Sci., 17: 886-892.
34. Sepkowitz, K.A., 2001. AIDS-the first 20 years. N. Engl. J. Med., 344: 1764-1772.
35. Shlay, J.C., G. Bartsch, G. Peng, J. Wang and C. Grunfeld et al., 2007. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-nonnucleoside reverse transcriptase inhibitor-or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J. Acquir. Immune Defic. Syndr., 44: 506-517.
36. Thompson, M.A., J.A. Aberg, P. Cahn, J.S.G. Montaner and G. Rizzardini et al., 2010. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the international AIDS society-USA panel. JAMA., 304: 321-333.
37. Walker, U.A. and K. Brinkman, 2001. NRTI induced mitochondrial toxicity as a mechanism for HAART related lipodystrophy: Fact or fiction? HIV Med., 2: 163-165.
38. Walli, R., O. Herfort, G.M. Michl, T. Demant and H. Jager et al., 1998. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr., 12: F167-F173